Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp12 | Adrenal and Neuroendocrine - Tumour | ECE2019

Functional mixed oncocytic adrenocortical neoplasm presenting as an asymptomatic adrenal mass

Racolta Niculina , Homsi Sarah , Keller Philippe , Lerintiu Felix , Linder V , Goichot Bernard , Smagala Agnes

Oncocytic adrenocortical neoplasm (OAN) represents a rare variant of adrenocortical carcinoma (ACC) with less than 150 cases reported in the literature. OANs account for 1.8% of adrenal masses, predominantly in adults and usually presenting as large tumors featuring hormonal secretion in 20% of cases. Accurate histological characterization of OANs is crucial as this subtype is believed to be more indolent in clinical behavior. There are 3 categories of OANs: pure oncocytic, mi...

ea0081p24 | Adrenal and Cardiovascular Endocrinology | ECE2022

Midnight ACTH vs morning ACTH levels in Cushing’s syndrome diagnosis

Bahougne Thibault , Homsi Sarah , Ortega Francoise , Munch Marion , Meyer Laurent , Reix Nathalie , Vix Michel , Cebula Helene , Goichot Bernard , Jeandidier Nathalie

Cushing’s syndrome (CS) is a rare and complex condition. Once the diagnosis of CS is confirmed, repetitive morning ACTH measurement is indicated to assess whether CS is ACTH dependent or independent. ACTH under 2,2 pmol/l characterises ACTH-independent CS and above 4,4 pmol/l ACTH-dependent CS. Some groups recommend midnight ACTH measurement rather than the morning. The purpose of our work was to evaluate 12PM ACTH vs 8AM ACTH measurement in the etiological diagnostic of ...

ea0063p826 | Adrenal and Neuroendocrine Tumours 3 | ECE2019

The French COMETE-Cancer network for adrenal cancer: 10 years of activity as part of a national plan for clinical care of rare cancers

Libe Rossella , Tabarin Antoine , Chabre Olivier , Laboureau Sandrine , Goichot Bernard , Vezzosi Delphine , Lefebvre Herve , Verges Bruno , Niccoli Patricia , Vanthyghem Marie-Christine , Baudin Eric , Bertherat Jerome

Introduction: The French National Institute of Cancer (INCa) launched supported by the Ministry of Health in 2008 a program for the recognition of national networks for the management of rare cancers. Among the 23 selected networks COMETE-Cancer was recognized by INCa in 2009 for Adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP). At that time 60–120 new ACC/year and 30 new MPP/year were expected at the national level....

ea0063oc5.1 | Adrenal 1 | ECE2019

Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma

Buffet Alexandre , Aim Laurene Ben , Leboulleux Sophie , Drui Delphine , Vezzosi Delphine , Libe Rossella , Ajzenberg Christiane , Bernardeschi Daniele , Cariou Bertrand , Chabolle Frederic , Chabre Olivier , Darrouzet Vincent , Delemer Brigitte , Desailloud Rachel , Goichot Bernard , Esvant Annabelle , Offredo Lucile , Herman Philippe , Laboureau Sandrine , Lefebvre Herve , Pierre Peggy , Raingeard Isabelle , Reznik Yves , Sadoul Jean-Louis , Hadoux Julien , Tabarin Antoine , Tauveron Igor , Zenaty Delphine , Favier Judith , Bertherat Jerome , Baudin Eric , Amar Laurence , Gimenez-Roqueplo Anne-Paule

Context: Paragangliomas and pheochromocytomas (PPGL) are rare neuroendocrine tumors, characterized by a strong genetic component. Indeed, up to 40% of patients carry a germline mutation in a PPGL susceptibility gene. In accordance with the international recommendations, genotyping of PPGL susceptibility genes is therefore proposed to all patients with PPGL, but it has actually never been shown whether the identification of a germline mutation in one PPGL susceptibility gene ch...